Daily weight-loss tablets are moving the obesity drug market beyond injections.
The new oral Wegovy from Novo Nordisk has recorded rapid early demand in the US.
Analysts say easier use could push the sector toward a $200bn value.
Patients are switching because pills are simpler and cheaper.
They avoid needles and do not need refrigeration.
Some users report steadier appetite control than with weekly shots.
Insurance coverage and falling prices are also driving uptake.
Rival Eli Lilly plans to launch its own tablet soon.
More companies are developing oral and combination treatments.
Injections still produce greater weight loss, so they will remain important for severe obesity.
Rising global obesity and limited public healthcare access are fuelling demand.
Experts say pills could make treatment more cost-effective and attract millions of new patients.
